Deloitte Corporate Finance Advisory acted as the exclusive financial advisor to the shareholders of hestomed nord in the sale of 100% of the shares to corpuls, a Nordic Capital portfolio company
About the transaction
The Deloitte Corporate Finance Advisory (“CFA”) team under the responsibility of Reiner Schwenk (Managing Director), led by Christoph Madea (Assistant Director) and supported by Alexander Völkel (Senior Associate) and Laurence Oleownik (Analyst) provided sell-side M&A lead advisory services and successfully advised the shareholders of hestomed nord GmbH (“hestomed nord”) in a structured process on the sale of 100% of the shares to GS Elektromedizinische Geräte G. Stemple GmbH (also known under the brand name “corpuls”), which is a portfolio company of Swedish private equity firm Nordic Capital.
hestomed nord, originally founded as Med-Fix GmbH in 1991, is a leading provider of emergency medical equipment with a geographical focus on Northern Germany. The company predominantly offers a range of defibrillators and thorax compression devices under exclusive sales & service partnership for corpuls. With more than 30 employees, hestomed nord serves a diversified customer base catering primarily to emergency medical services and medical service providers (mainly hospitals).
corpuls is a leading global medical technology provider, focusing on high-quality and innovative products for professional users in emergency situations, which was founded in 1982 by Günter Stemple and has been majority-owned by Nordic Capital since 2023.
“This step will enable us to combine our forces even more and thus offer our customers even better service and further expand our market position”, said Christian Klimmer, CEO of corpuls.
Sven Larsen, Managing Director of hestomed nord, added: “This merger with one of the leading medical technology manufacturers will open up a lot of opportunities for us. corpuls has big plans for the next few years and the signs are pointing towards expansion. And we are now part of this exciting and promising progression.”
Deloitte CFA provided tailored M&A lead advisory services and executed the deal with exceptional speed and efficiency, culminating in a successful signing on December 4th and a value-adding final result to the shareholders of hestomed nord.
On the legal side, shareholders of hestomed nord were supported by LUPP + PARTNER while corpuls was advised by Oldenbourg & Pauls.
About the Client
hestomed nord, a subsidiary of hestomed Group based in Stockelsdorf, Schleswig-Holstein, is a sales organization specializing in medical devices and associated services, in addition to offering medical consumables, targeting the emergency medical industry with a focus on Northern Germany.
Besides acting as exclusive territorial representative for corpuls in Northern Germany, hestomed nord’s offering encompasses respiratory equipment from Dräger, infusion technology from B. Braun and hestomed Group’s proprietary own products.
About the Buyer
The medical technology company based in Kaufering, Bavaria, has been developing and manufacturing innovative high-end devices for emergency and intensive care medicine for over 40 years. With now well over 600 employees, corpuls exports defibrillators, monitoring systems and thorax compression devices for cardiopulmonary resuscitation in the event of cardiac arrest, as well as digital solutions in the field of telemedicine and quality management, to 70 countries worldwide.
About Deloitte – Corporate Finance Advisory
As leading independent M&A advisors, we provide M&A deal execution and financial advisory services to large and mid-market corporations as well as to private equity firms globally. We offer financial advice and insight at every stage of a transaction – from consideration of strategic options to transaction execution, be it an IPO, acquisition, or divestment, restructuring or fast-track disposal. We pride ourselves in our independent advice to our clients.
Deal contacts:
Reiner Schwenk, Managing Director: +49 152 0931 0467, rschwenk@deloitte.de
Christoph Madea, Assistant Director: +49 151 5800 5122, cmadea@deloitte.de